Evaluating Safety of Escalating Doses of Tilmanocept by IV Injection and SPECT Imaging in Subjects With and Without RA
Status:
Completed
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
Prospective, open-label, multicenter, dose escalation, safety with pharmacokinetics (PK) and
dosimetry study of injected Tc 99m tilmanocept in the detection of and assessment of
localization to skeletal joints in subjects with and without active RA by SPECT imaging.